Does CareFirst BlueCross BlueShield Cover Wegovy?
The verdict
Conditional on most plans
CareFirst BlueCross BlueShield covers Wegovy for weight management on large-employer commercial plans (Tier 2 or Tier 4 with prior authorization), but explicitly excludes it on ACA/Exchange plans. The coverage outcome depends on a single fact: whether coverage came through a large employer or the ACA marketplace. Medicare covers the cardiovascular risk reduction indication only.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with CareFirst BlueCross BlueShield using your member ID.
Key facts
CareFirst BlueCross BlueShield places Wegovy on Tier 2 or Tier 4 as an anti-obesity drug for large-group commercial plans and explicitly excludes it from ACA/Exchange plans — one of the clearer large-group/Exchange distinctions among Blue affiliates.
CareFirst BlueCross BlueShield formulary and coverage policy
CareFirst's PA for large-group Wegovy coverage requires documented prior weight-loss attempts — a specific requirement that some other plans do not mandate at the initial PA stage.
CareFirst BlueCross BlueShield coverage criteria
Wegovy is FDA-approved for chronic weight management (BMI 30+, or 27+ with a weight-related comorbidity) and for cardiovascular risk reduction in adults with established CVD — it is a weight-loss and CV drug, not a diabetes drug.
FDA, Wegovy (semaglutide) prescribing information
Medicare vs. commercial coverage
Whether CareFirst BlueCross BlueShield covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D cannot cover Wegovy for weight loss by federal statute. For CareFirst Medicare members with established cardiovascular disease who are overweight or obese, the cardiovascular risk reduction indication is coverable under Part D with prior authorization. The $2,100 beneficiary OOP cap applies in 2026. The Medicare GLP-1 Bridge (launching July 1, 2026, through December 31, 2027) provides weight-loss access to Wegovy at a fixed $50 per month copay outside Part D — this does not count toward the deductible, TrOOP, or the $2,100 cap. Bridge eligibility requires provider attestation: BMI 35 or higher; or BMI 30 or higher with heart failure, uncontrolled hypertension, or CKD; or BMI 27 or higher with prediabetes, prior MI, prior stroke, or symptomatic PAD. Members already receiving a Part D-covered GLP-1 are ineligible. Medicare beneficiaries cannot use the NovoCare savings card.
Commercial / Employer
Group & marketplace plans
CareFirst operates in Maryland, DC, and Virginia and is notably more transparent than many Blue affiliates. Large-employer commercial plans place Wegovy on Tier 2 or Tier 4 as an anti-obesity drug, covered with prior authorization requiring documented prior weight-loss attempts and BMI criteria. ACA/Exchange plans explicitly exclude Wegovy — this is not a PA denial but a benefit exclusion for that line of business. Medicaid coverage for MD and DC is state-dependent; non-weight-loss FDA indications are covered under applicable Medicaid programs. The single most important question for a CareFirst member is whether coverage came through a large employer or the ACA marketplace — that one fact determines the answer.
The 5 boxes you must tick to get approved
Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349 per month (Novo Nordisk published list price for a 28-day supply); this is the default for ACA/Exchange CareFirst members, who face an explicit exclusion
List price with no coverage — before any manufacturer savings card.
With coverage
Large-group commercial: Tier 2 or Tier 4 cost-share (plan-specific; verify with CareFirst). NovoCare Wegovy Savings Offer: commercially insured large-group members whose plan covers Wegovy may pay as little as $25 per month (max savings $100 per 28-day supply). ACA/Exchange: not covered; cash only. Medicare CV indication: Part D cost-share depends on tier and benefit phase; $2,100 OOP cap 2026. Medicare Bridge (weight loss, from 7/1/2026): fixed $50 per month outside Part D.
Typical monthly copay once prior authorization is approved.
Bridge program
NovoCare self-pay program: approximately $199 per month for starting doses (0.25/0.5 mg, first two fills through December 31, 2026), then approximately $349 per month for standard doses. Not available to Medicare or Medicaid beneficiaries. ACA/Exchange members excluded from coverage may use the self-pay program. From January 1, 2027, Novo Nordisk has announced a list-price reduction to approximately $675 per month; the IRA-negotiated Maximum Fair Price of $274 per 30-day supply also takes effect January 1, 2027.
Reduced copay through the assistance program, where eligible.
All figures are estimates. Actual cost-share varies by plan tier and pharmacy. Confirm with CareFirst member services or the plan drug-lookup tool.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Determine whether your CareFirst plan is large-group or ACA/Exchange
Ask your HR department or check your insurance card. CareFirst's Wegovy coverage applies to large-employer commercial plans (Tier 2 or Tier 4 with PA) and is explicitly excluded from ACA/Exchange plans. This single fact determines your coverage path before any other step.
- 2
Confirm tier and PA requirements on the CareFirst large-group formulary
If you are on a large-group CareFirst plan, confirm the specific tier (Tier 2 or Tier 4) and prior-authorization requirements — including the prior weight-loss attempts documentation requirement — on the CareFirst formulary or by calling CareFirst member services.
- 3
Ask your prescriber about the CV indication or Bridge eligibility if applicable
If you have established cardiovascular disease and are overweight or obese, ask your provider about the cardiovascular risk reduction indication. Medicare CareFirst members should ask about the GLP-1 Bridge (launching July 1, 2026, $50/month outside Part D).
Options if CareFirst BlueCross BlueShield won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
CareFirst large-group formulary Tier 2/4 (where applicable)
CareFirst large-employer commercial members can access Wegovy at Tier 2 or Tier 4 with prior authorization. Confirm the tier and cost-share with CareFirst and ensure the required documentation of prior weight-loss attempts is prepared before submitting PA.
Cardiovascular indication (Medicare Part D or commercial)
Wegovy is FDA-approved for cardiovascular risk reduction in adults with established CVD who are overweight or obese. This indication may be coverable under Medicare Part D or certain CareFirst commercial plans with prior authorization, separate from the weight-loss benefit.
Medicare GLP-1 Bridge
Launching July 1, 2026, the Bridge provides eligible Medicare beneficiaries weight-loss access to Wegovy at $50 per month through December 31, 2027, outside Part D. Eligibility criteria apply; members already on a Part D-covered GLP-1 are ineligible.
Compounded semaglutide
Compounded semaglutide, available through licensed telehealth platforms, does not require insurance prior authorization. Starting from $49 per month. Compounded semaglutide is not the same medication as Wegovy and has not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
It depends entirely on your plan type. CareFirst covers Wegovy for weight management on large-employer commercial plans at Tier 2 or Tier 4, with prior authorization requiring documented BMI and prior weight-loss attempts. ACA/Exchange CareFirst plans explicitly exclude Wegovy — this is a benefit exclusion with no PA path. The first question to answer is whether your coverage came through a large employer or the ACA marketplace.
Large-employer groups have the ability to purchase an anti-obesity drug benefit as part of their benefits package, and CareFirst includes Wegovy on the large-group formulary for employers that do. ACA/individual exchange plans are regulated differently and tend to exclude weight-loss drugs — the ACA's essential health benefits requirement does not mandate coverage of anti-obesity medications. This large-group versus Exchange split is a feature of how CareFirst has structured its benefit tiers, not an inconsistency in clinical coverage.
For CareFirst large-group commercial members, prior authorization requires documentation of your BMI (30 or higher, or 27 or higher with a weight-related comorbidity) and documented prior weight-loss attempts. Your prescriber submits the PA to CareFirst. Wegovy is placed on Tier 2 or Tier 4, so cost-share will depend on which tier applies to your specific plan. Verify exact criteria on the CareFirst formulary or call CareFirst member services before submitting.
Large-group commercial CareFirst members whose plan covers Wegovy may use the NovoCare Wegovy Savings Offer (as little as $25 per month, max savings $100 per 28-day supply). ACA/Exchange members whose plan excludes Wegovy cannot use the savings card at standard retail — it applies only where the plan covers the drug. Medicare and Medicaid beneficiaries cannot use the card due to federal anti-kickback rules. ACA exchange and state-employee plans are not treated as government programs for this offer.
CareFirst is notably more transparent than BCBS of Alabama on Wegovy coverage. CareFirst publishes a specific formulary structure — large-group Tier 2 or Tier 4 coverage with PA, and an explicit ACA/Exchange exclusion — giving members a concrete answer based on their plan type. BCBS of Alabama does not publish drug-level Wegovy detail and directs members to verify through the drug-lookup tool. Both are Blue affiliates, but with different levels of formulary transparency and different state market contexts.
Related Articles
Does CareFirst BlueCross BlueShield Cover Mounjaro? 2026 | Curex
CareFirst BlueCross BlueShield (MD/DC/VA) covers Mounjaro for type 2 diabetes with prior authorization — not weight loss. Medicaid state-dependent.
Read moreDoes CareFirst BlueCross BlueShield Cover Prolia? 2026 | Curex
CareFirst BCBS (MD/DC/N.VA) covers Prolia under the medical benefit with PA. Jubbonti preferred at several BCBS licensees now. Verify at carefirst.com.
Read moreDoes BCBS of Arizona Cover Wegovy? 2026 Guide | Curex
BCBS of Arizona covers Wegovy only where your employer opted in; formulary not published. Verify via drug-lookup and confirm with HR first.
Read moreDoes Blue Cross Blue Shield Cover Wegovy? 2026 | Curex
BCBS is 33+ independent affiliates — no single Wegovy answer. Trend favors exclusion in 2025-2026. Find your affiliate and verify your formulary.
Read moreDoes BCBS Alabama Cover Wegovy? 2026 Guide | Curex
BCBS Alabama Wegovy coverage is employer-dependent and unpublished. Alabama Medicaid excludes obesity GLP-1s. How to verify your specific plan.
Read moreDoes CareFirst BlueCross BlueShield Cover Ozempic? 2026 | Curex
CareFirst covers Ozempic for type 2 diabetes with prior auth — not weight loss. FEHB T2D enrollees may use the NovoCare $25 card. Verify on plan lookup.
Read moreWhether or not CareFirst covers Wegovy, there's a path that skips insurance
CareFirst covers Wegovy on large-group plans but explicitly excludes it on ACA/Exchange plans. For Exchange members and anyone facing the exclusion, compounded semaglutide from $49/mo (compounded tirzepatide from $149/mo) is available at Curex — no insurance, no prior authorization. Compounded semaglutide is not the same medication as Wegovy. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with CareFirst BlueCross BlueShield before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.